Tag: ovarianCancer

Articles

• BRCA1 and BRCA2 mutation carriers
• Lobular breast cancer and LCIS characteristics

News

07/22/22

Mortality after some second cancers may be higher for breast cancer survivors

02/09/14

Young birth control pill use heightens BC risk in BRCA1 carriers

01/10/12

Father's breast cancer or BRCA mutation influences daughter's risk

10/18/11

Previous appendectomy linked to cancer in Jewish BRCA carriers

Studies

• Exploring the Association Between Hair Dye Use and Human Cancers: A Systematic Review Cite
  Greene RK, Maghfour J, Nguyen C, Baker G, Mesinkovska NA. Exploring the Association Between Hair Dye Use and Human Cancers: A Systematic Review. JAAD International. Elsevier BV; 2025; 10.1016/j.jdin.2025.10.009
• Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer Cite
  Fabi A, Franco A, Cortesi L, Lucci Cordisco E, Rossi A, Terribile DA, et al. Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer. JNCI Cancer Spectrum. Oxford University Press (OUP); 2025; 10.1093/jncics/pkaf097
• A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation Cite
  He J, Zhang Y, He Z, Zheng L. A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation. Frontiers in Oncology. Frontiers Media SA; 2025; 15 10.3389/fonc.2025.1579470
• GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity Cite
  Dai H, Li Y, Lee YA, Lu Y, George TJ, Donahoo WT, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology. American Medical Association (AMA); 2025; 10.1001/jamaoncol.2025.2681
• Promising effect of cisplatin and melatonin combination on the inhibition of cisplatin resistance in ovarian cancer Cite
  Adeya Adella C, Siregar MFG, Putra IB, Hasibuan PA, Andrijono A, Bachtiar A, et al. Promising effect of cisplatin and melatonin combination on the inhibition of cisplatin resistance in ovarian cancer. F1000Research. F1000 Research Ltd; 2025; 12:313 10.12688/f1000research.130172.4
• Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer Cite
  Chen L, Fan T, Wang M, Zhu C, Feng W, Li Y, et al. Myricetin, a natural inhibitor of CD147, increases sensitivity of cisplatin in ovarian cancer. Expert Opinion on Therapeutic Targets. Informa UK Limited; 2024; 28:83-95 10.1080/14728222.2024.2306345
• Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure Cite
  Yoshihama T, Yokota M, Aoki D, Yamagami W. Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2025; 10.1093/jjco/hyaf092
• Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers Cite
  Tuesley KM, Spilsbury K, Pearson S, Donovan P, Obermair A, Coory MD, et al. Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2025; 117:1046-1055 10.1093/jnci/djae282
• Fiber-type prebiotics and gynecological and breast cancers risk: the PrebiotiCa study Cite
  Turati F, Esposito G, Concina F, Fiori F, Parpinel M, Parazzini F, et al. Fiber-type prebiotics and gynecological and breast cancers risk: the PrebiotiCa study. American Journal of Epidemiology. Oxford University Press (OUP); 2024; 193:1693-1700 10.1093/aje/kwae130
• Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.01146
• Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy Cite
  Gootzen T, Steenbeek M, van Bommel M, IntHout J, Kets C, Hermens R, et al. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s10689-024-00412-0
• Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden Cite
  Yi H, Zhang N, Huang J, Zheng Y, Hong Qh, Sundquist J, et al. Association of Levonorgestrel-Releasing Intrauterine Device with Gynecologic and Breast Cancers: National Cohort Study in Sweden. American Journal of Obstetrics and Gynecology. Elsevier BV; 2024; 10.1016/j.ajog.2024.05.011
• Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors Cite
  Zhang B, Brantley K, Rosenberg S, Kirkner G, Collins L, Ruddy K, et al. Abstract PO3-11-10: Second primary non-breast cancers in young breast cancer survivors. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO3-11-10-PO3-11-10 10.1158/1538-7445.sabcs23-po3-11-10
• Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:7321-7321 10.1158/1538-7445.am2024-7321
• Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations Cite
  Kotsopoulos J, Gronwald J, Huzarski T, Møller P, Pal T, McCuaig JM, et al. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2023.6937
• Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer Cite
  Xiao Q, Mao X, Ploner A, Grassmann F, Rodriguez J, Eriksson M, et al. Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae030
• Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review Cite
  Sailo BL, Liu L, Chauhan S, Girisa S, Hegde M, Liang L, et al. Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review. Cancers. MDPI AG; 2024; 16:244 10.3390/cancers16020244
• Causal effects of exposure to ambient air pollution on cancer risk: Insights from genetic evidence Cite
  Li W, Wang W. Causal effects of exposure to ambient air pollution on cancer risk: Insights from genetic evidence. Science of The Total Environment. Elsevier BV; 2023;:168843 10.1016/j.scitotenv.2023.168843
• Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC) Cite
  Madrigal LF, Garcé MYR, Ruiz FJJ. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC). Current Problems in Cancer. Elsevier BV; 2023;:101008 10.1016/j.currproblcancer.2023.101008
• Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review Cite
  Jahanfar S, Mortazavi J, Lapidow A, Cu C, Abosy JA, Morris K, et al. Assessing the impact of contraceptive use on cancer risk among women of reproductive age – a systematic review. Research Square Platform LLC; 2023; 10.21203/rs.3.rs-3191980/v1
• Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer Cite
  Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, et al. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11229-y
• Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of estrogen receptor–specific breast cancer by family history of estrogen receptor subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China Cite
  Peng S, Dong S, Gong C, Chen X, Du H, Zhan Y, et al. Evidence-based identification of breast cancer and associated ovarian and uterus cancer risk components in source waters from high incidence area in the Pearl River Basin, China. Science of The Total Environment. Elsevier BV; 2023;:166060 10.1016/j.scitotenv.2023.166060
• Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review Cite
  Ferris JS, Morgan DA, Tseng AS, Terry MB, Ottman R, Hur C, et al. Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review. Critical Reviews in Oncology/Hematology. Elsevier BV; 2023;:104081 10.1016/j.critrevonc.2023.104081
• Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines Cite
  Abdelaal G, Carter A, Cheung W, Panayiotidis M, Racey S, Tétard D, et al. Novel Iron Chelator SK4 Drives Cytotoxicity through Inhibiting Mitochondrial Metabolism in Ovarian and Triple Negative Breast Cancer Cell Lines. Biomedicines. MDPI AG; 2023; 11:2073 10.3390/biomedicines11072073
• Risk of ER-specific breast cancer by family history of ER subtypes and other cancers Cite
  Wang Q, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad104
• Familial aggregation of early‐onset cancers in early‐onset breast cancer families Cite
  Rantala JNJ, Heikkinen SMM, Hirvonen EM, Tanskanen T, Malila NK, Pitkäniemi JM. Familial aggregation of early‐onset cancers in early‐onset breast cancer families. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34538
• Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records Cite
  Hassan H, Allen I, Rahman T, Allen S, Knott C, Huntley C, et al. Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records. The Lancet Oncology. Elsevier BV; 2025; 10.1016/s1470-2045(25)00156-1
• Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience Cite
  Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, et al. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2023; 10.1093/jjco/hyad020
• Molecular characteristics of Asian male BRCA-related cancers Cite
  Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL, Ma ESK. Molecular characteristics of Asian male BRCA-related cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 198:391-400 10.1007/s10549-022-06651-y
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis Cite
  Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K, et al. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers. MDPI AG; 2023; 15:1625 10.3390/cancers15051625
• The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cite
  Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. Wiley; 2022; 129:901-907 10.1002/cncr.34615
• Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis Cite
  Allen I, Hassan H, Sofianopoulou E, Eccles D, Turnbull C, Tischkowitz M, et al. Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01610-x
• Ultra-processed food consumption, cancer risk and cancer mortality: a large-scale prospective analysis within the UK Biobank Cite
  Chang K, Gunter MJ, Rauber F, Levy RB, Huybrechts I, Kliemann N, et al. Ultra-processed food consumption, cancer risk and cancer mortality: a large-scale prospective analysis within the UK Biobank. eClinicalMedicine. Elsevier BV; 2023;:101840 10.1016/j.eclinm.2023.101840
• The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review Cite
  Krejbich P, Birringer M. The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review. Antioxidants. MDPI AG; 2022; 11:2149 10.3390/antiox11112149
• Surgical management of BRCA-mutation carriers: A single institution experience Cite
  Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, et al. Surgical management of BRCA-mutation carriers: A single institution experience. European Journal of Surgical Oncology. Elsevier BV; 2022; 48:1706-1712 10.1016/j.ejso.2022.04.024
• Network Pharmacology, Integrated Bioinformatics, and Molecular Docking Reveals the Anti-Ovarian Cancer Molecular Mechanisms of Cinnamon (Cinnamomum cassia (L.) J. Presl) Cite
  Chen B, Jin X, Wang H, Zhou Q, Li G, Lu X. Network Pharmacology, Integrated Bioinformatics, and Molecular Docking Reveals the Anti-Ovarian Cancer Molecular Mechanisms of Cinnamon (Cinnamomum cassia (L.) J. Presl). Natural Product Communications. SAGE Publications; 2022; 17:1934578X2211191 10.1177/1934578x221119118
• Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal Cite
  Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2022; 31:1351-1358 10.1158/1055-9965.epi-21-1196
• Anticancer Potential of Cinnamon Bark Extract (Cinnamomum burmanii) with Cisplatin Combination against P-glycoprotein and Apoptotic Influx Biomarkers Cite
  Dina S, Siregar MFG, Jusuf NK, Hasibuan PA, Andrijono A, Bachtiar A, et al. Anticancer Potential of Cinnamon Bark Extract (Cinnamomum burmanii) with Cisplatin Combination against P-glycoprotein and Apoptotic Influx Biomarkers. Open Access Macedonian Journal of Medical Sciences. Scientific Foundation SPIROSKI; 2022; 10:958-964 10.3889/oamjms.2022.9420
• Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland Cite
  Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-10519-y
• Pre-diagnosis meat intake and cooking method and ovarian cancer survival: results from the Ovarian Cancer Follow-Up Study (OOPS) Cite
  Wei Y, Sun M, Wen Z, Liu F, Liu Y, Yan S, et al. Pre-diagnosis meat intake and cooking method and ovarian cancer survival: results from the Ovarian Cancer Follow-Up Study (OOPS). Food & Function. Royal Society of Chemistry (RSC); 2022; 10.1039/d1fo03825g
• Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study Cite
  Kim H, Kim SS, Lee JS, Yoon JS, Shin HJ, Lee JE, et al. Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-12-25-P3-12-25 10.1158/1538-7445.sabcs21-p3-12-25
• Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer? Cite
  Lemon LS, Orr B, Modugno F, Buckanovich RJ, Coffman L, Edwards RP, et al. Metformin and survival: Is there benefit in a cohort limited to diabetic women with endometrial, breast, or ovarian cancer?. Gynecologic Oncology. Elsevier BV; 2022; 10.1016/j.ygyno.2022.01.022
• Dietary fish and omega-3 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis Cite
  Wang Y, Liu K, Long T, Long J, Li Y, Li J, et al. Dietary fish and omega-3 polyunsaturated fatty acids intake and cancer survival: A systematic review and meta-analysis. Critical Reviews in Food Science and Nutrition. Informa UK Limited; 2022;:1-17 10.1080/10408398.2022.2029826
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies Cite
  Park J, Huang D, Chang YJ, Lim MC, Myung S. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies. Carcinogenesis. Oxford University Press (OUP); 2021; 10.1093/carcin/bgab107
• Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer Cite
  Nañez A, Stram DA, Bethan Powell C, Garcia C. Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer. Gynecologic Oncology Reports. Elsevier BV; 2022; 39:100899 10.1016/j.gore.2021.100899
• Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies Cite
  Byun D, Hong S, Ryu S, Nam Y, Jang H, Cho Y, et al. Early-life body mass index and risks of breast, endometrial, and ovarian cancers: a dose–response meta-analysis of prospective studies. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-021-01625-1
• Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study Cite
  Zheng G, Sundquist J, Sundquist K, Ji J. Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08925-y
• Risk-Reducing Salpingo-oophorectomy (RRSO) Cite
  Kobayashi Y, Aoki D. Risk-Reducing Salpingo-oophorectomy (RRSO). Hereditary Breast and Ovarian Cancer. Springer Singapore; 2021;:183-191 10.1007/978-981-16-4521-1_12
• Potential effets of ginkgo (Ginkgo biloba, L.) on female reproduction Cite
  Sirotkin AV. Potential effets of ginkgo (Ginkgo biloba, L.) on female reproduction. Reproductive Biology. Elsevier BV; 2021; 21:100568 10.1016/j.repbio.2021.100568
• Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis Cite
  Adani G, Filippini T, Wise LA, Halldorsson TI, Blaha L, Vinceti M. Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:1095-1106 10.1158/1055-9965.epi-19-1628
• Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer Cite
  Huang K, Liu Y, Hsu Y, Kuo W. Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer. Healthcare. MDPI AG; 2021; 9:1203 10.3390/healthcare9091203
• Ursolic acid protects against cisplatin‑induced ototoxicity by inhibiting oxidative stress and TRPV1‑mediated Ca2+‑signaling Cite
  Di Y, Xu T, Tian Y, Ma T, Qu D, Wang Y, et al. Ursolic acid protects against cisplatin‑induced ototoxicity by inhibiting oxidative stress and TRPV1‑mediated Ca2+‑signaling. International Journal of Molecular Medicine. Spandidos Publications; 2020; 46:806-816 10.3892/ijmm.2020.4633
• Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status Cite
  Sung H, Freedman RA, Siegel RL, Hyun N, DeSantis CE, Ruddy KJ, et al. Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. Cancer. Wiley; 2021; 10.1002/cncr.33602
• Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy Cite
  Wang C, Hu K, Deng L, He W, Fang F, Tamimi RM, et al. Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy. BMC Cancer. Springer Science and Business Media LLC; 2021; 21 10.1186/s12885-021-08132-9
• Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study Cite
  Baik S, McDonald C. Effects of Hormone Therapy on survival, cancer, cardiovascular and dementia risks in 1.5 million women over age 65: a retrospective observational study. Authorea, Inc.; 2021; 10.22541/au.161873076.60547427/v1
• Correlation between family history and characteristics of breast cancer Cite
  Liu L, Hao X, Song Z, Zhi X, Zhang S, Zhang J. Correlation between family history and characteristics of breast cancer. Scientific Reports. Springer Science and Business Media LLC; 2021; 11 10.1038/s41598-021-85899-8
• Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women Cite
  Arthur RS, Kirsh VA, Mossavar-Rahmani Y, Xue X, Rohan TE. Sugar-containing beverages and their association with risk of breast, endometrial, ovarian and colorectal cancers among Canadian women. Cancer Epidemiology. Elsevier BV; 2020; 70:101855 10.1016/j.canep.2020.101855
• Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018 Cite
  Guo F, Scholl M, Fuchs EL, Wong R, Kuo Y, Berenson AB. Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018. JAMA Network Open. American Medical Association (AMA); 2020; 3:e2024358 10.1001/jamanetworkopen.2020.24358
• Time for BRCA Testing Among Women 65 Years or Older in the United States Cite
  Burton RC. Time for BRCA Testing Among Women 65 Years or Older in the United States. JAMA Network Open. American Medical Association (AMA); 2020; 3:e2024921 10.1001/jamanetworkopen.2020.24921
• Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers Cite
  Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, et al. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. The American Surgeon. SAGE Publications; 2020; 86:1243-1247 10.1177/0003134820964208
• Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers Cite
  Huang Y, Wang K, Chen H, Chiang Y, Hsia S. Protective Effects of Epigallocatechin Gallate (EGCG) on Endometrial, Breast, and Ovarian Cancers. Biomolecules. MDPI AG; 2020; 10:1481 10.3390/biom10111481
• Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study Cite
  Zhang Y, Birmann BM, Han J, Giovannucci EL, Speizer FE, Stampfer MJ, et al. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ. BMJ; 2020;:m2942 10.1136/bmj.m2942
• Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study Cite
  Sundbøll J, Farkas DK, Adelborg K, Schapira L, Tamang S, Nørgaard M, et al. Risk of primary urological and genital cancers following incident breast cancer: a Danish population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:825-837 10.1007/s10549-020-05879-w
• The risk of female-specific cancer after bariatric surgery in the state of New York Cite
  Tsui ST, Yang J, Zhang X, Spaniolas K, Kim S, Griffin T, et al. The risk of female-specific cancer after bariatric surgery in the state of New York. Surgical Endoscopy. Springer Science and Business Media LLC; 2020; 10.1007/s00464-020-07915-8
• Abstract 4667: Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts Cite
  Hurwitz LM, Michels KA, Cook MB, Pfeiffer RM, Trabert B. Abstract 4667: Associations between daily aspirin use and cancer risk across strata of major cancer risk factors in two large U.S. cohorts. Epidemiology. American Association for Cancer Research; 2020; 10.1158/1538-7445.am2020-4667
• The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes Cite
  Eid SY, Althubiti MA, Abdallah ME, Wink M, El-Readi MZ. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes. Phytomedicine. Elsevier BV; 2020; 77:153280 10.1016/j.phymed.2020.153280
• Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis Cite
  Adani G, Filippini T, Wise LA, Halldorsson TI, Blaha L, Vinceti M. Dietary Intake of Acrylamide and Risk of Breast, Endometrial, and Ovarian Cancers: A Systematic Review and Dose–Response Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2020; 29:1095-1106 10.1158/1055-9965.epi-19-1628
• Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status Cite
  Roberson ML, Robinson WR, Nichols HB, Olshan AF, Troester MA. Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp18-c052
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review Cite
  Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 301:875-884 10.1007/s00404-020-05458-w
• Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines Cite
  Al‑Yousef N, Shinwari Z, Al‑Shahrani B, Al‑Showimi M, Al‑Moghrabi N. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncology Reports. Spandidos Publications; 2020; 10.3892/or.2020.7473
• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer Cite
  Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA. American Medical Association (AMA); 2019; 322:652 10.1001/jama.2019.10987
• Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment Cite
  Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology. Springer Science and Business Media LLC; 2019; 42:815-828 10.1007/s13402-019-00464-w
• Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation. Cite
  Safra T, Waissengrin B, Gerber D, Bernstein Molho R, Amit A, Salman L, et al. Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e13062-e13062 10.1200/jco.2019.37.15_suppl.e13062
• Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center Cite
  Frey MK, Kopparam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, et al. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. Cancer. Wiley; 2018; 125:690-697 10.1002/cncr.31856
• The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans Cite
  Kim H, Choi DH, Park W, Im Y, Ahn JS, Park YH, et al. The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice. Springer Science and Business Media LLC; 2019; 17 10.1186/s13053-018-0103-3
• Work stress and the risk of cancer: A meta‐analysis of observational studies Cite
  Yang T, Qiao Y, Xiang S, Li W, Gan Y, Chen Y. Work stress and the risk of cancer: A meta‐analysis of observational studies. International Journal of Cancer. Wiley; 2018; 144:2390-2400 10.1002/ijc.31955
• The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study Cite
  Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4353-2
• Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival Cite
  Khadge S, Thiele GM, Sharp JG, McGuire TR, Klassen LW, Black PN, et al. Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival. Clinical & Experimental Metastasis. Springer Science and Business Media LLC; 2018; 35:797-818 10.1007/s10585-018-9941-7
• The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations Cite
  Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:151-157 10.1007/s10549-018-4887-7
• What if I keep my breasts? Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study. Cite
  Warner E, Zhu S, Hill K, Causer P, Jong RA, Yaffe M, et al. What if I keep my breasts? Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1523-1523 10.1200/jco.2018.36.15_suppl.1523
• Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation Cite
  Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. Elsevier BV; 2018; 150:85-91 10.1016/j.ygyno.2018.05.011
• Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers Cite
  Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology. American Medical Association (AMA); 2018; 4:1059 10.1001/jamaoncol.2018.0211
• Multiple primary non-breast tumors in breast cancer survivors Cite
  Corso G, Veronesi P, Santomauro GI, Maisonneuve P, Morigi C, Peruzzotti G, et al. Multiple primary non-breast tumors in breast cancer survivors. Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC; 2018; 144:979-986 10.1007/s00432-018-2621-9
• Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis Cite
  Li Z, Wu Q, Song J, Zhang Y, Zhu S, Sun S. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis. Hormones and Cancer. Springer Science and Business Media LLC; 2018; 9:197-204 10.1007/s12672-018-0330-0
• Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway Cite
  Gong C, Yang Z, Zhang L, Wang Y, Gong W, Liu Y. Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway. OncoTargets and Therapy. Informa UK Limited; 2017; Volume 11:17-27 10.2147/ott.s147316
• Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women Cite
  Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncology. American Medical Association (AMA); 2017; 3:1647 10.1001/jamaoncol.2017.1996
• BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers Cite
  Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications. Springer Science and Business Media LLC; 2017; 8 10.1038/s41467-017-00388-9
• Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neuropathic pain in the rat Cite
  Galley HF, McCormick B, Wilson KL, Lowes DA, Colvin L, Torsney C. Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neuropathic pain in the rat. Journal of Pineal Research. Wiley; 2017; 63:e12444 10.1111/jpi.12444
• Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages Cite
  Woo J, Ahn J, Jang DS, Lee K, Choi J. Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages. Journal of Agricultural and Food Chemistry. American Chemical Society (ACS); 2017; 65:7893-7899 10.1021/acs.jafc.7b01543
• Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast Cite
  Mathew A, Rajagopal P, Villgran V, Sandhu G, Jankowitz R, Jacob M, et al. Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe und Frauenheilkunde. Georg Thieme Verlag KG; 2017; 77:660-666 10.1055/s-0043-109374
• Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes Cite
  Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, et al. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes. Gynecologic Oncology. Elsevier BV; 2017; 146:123-128 10.1016/j.ygyno.2017.04.009
• Fatty acid intake and erythrocyte fatty acid profile in women with breast, ovarian and cervical cancers Cite
  Bannikoppa P, Dhayanand J, Madhukumar R, Padmanabhan A, Bafna U, Vijayakumar M, et al. Fatty acid intake and erythrocyte fatty acid profile in women with breast, ovarian and cervical cancers. Clinical Nutrition ESPEN. Elsevier BV; 2017; 19:59-63 10.1016/j.clnesp.2017.03.001
• Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women Cite
  Schmidt MK, van den Broek AJ, Tollenaar RAEM, Smit VTHBM, Westenend PJ, Brinkhuis M, et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 109 10.1093/jnci/djw329
• Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers Cite
  Chen F, Zhang J, Fang X, Yu H, Liu Y, Li H, et al. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers. Acta Pharmacologica Sinica. Springer Science and Business Media LLC; 2017; 38:859-873 10.1038/aps.2016.150
• Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a “bedside-to-bench” approach Cite
  Ben-Arye E, Lavie O, Samuels N, Khamaisie H, Schiff E, Raz OG, et al. Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a “bedside-to-bench” approach. Medical Oncology. Springer Science and Business Media LLC; 2017; 34 10.1007/s12032-017-0910-9
• The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis Cite
  Song J, Chen C, Yuan J, Sun S. The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis. Familial Cancer. Springer Science and Business Media LLC; 2017; 16:339-349 10.1007/s10689-017-9969-x
• Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers Cite
  Manna P, Molehin D, Ahmed A. Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers. Progress in Molecular Biology and Translational Science. Elsevier; 2016;:487-537 10.1016/bs.pmbts.2016.10.002
• Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients Cite
  Jung J, Kang E, Gwak J, Seo A, Park S, Lee A, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Current Oncology. MDPI AG; 2016; 23:298 10.3747/co.23.3054
• Differences in survival for patients with familial and sporadic cancer Cite
  Lee M, Reilly M, Lindström LS, Czene K. Differences in survival for patients with familial and sporadic cancer. International Journal of Cancer. Wiley; 2016; 140:581-590 10.1002/ijc.30476
• Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M Cite
  Shewell L, Wang J, Paton J, Paton A, Day C, Jennings M. Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Biochemical and Biophysical Research Communications. Elsevier BV; 2018; 507:173-177 10.1016/j.bbrc.2018.11.001
• Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up Cite
  Dagan E, Gershoni-Baruch R, Kurolap A, Fried G. Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up. European Journal of Cancer Care. Wiley; 2016; 26:e12594 10.1111/ecc.12594
• Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study Cite
  Vaughan LE, Prizment A, Blair CK, Thomas W, Anderson KE. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:1395-1402 10.1007/s10552-016-0804-8
• Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort Cite
  Donat-Vargas C, Åkesson A, Berglund M, Glynn A, Wolk A, Kippler M. Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:1113-1121 10.1038/bjc.2016.282
• Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers Cite
  Lee Y, Lee S, Kim K, Jung K, Lee J, Kim Y. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Journal of Gynecologic Oncology. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy; 2017; 28 10.3802/jgo.2017.28.e3
• High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients Cite
  Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, et al. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2698-y
• Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas Cite
  Pinto P, Peixoto A, Santos C, Rocha P, Pinto C, Pinheiro M, et al. Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0161438 10.1371/journal.pone.0161438
• Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers Cite
  Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, et al. Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. The Oncologist. Wiley; 2016; 21:869-874 10.1634/theoncologist.2015-0354
• Douching, Talc Use, and Risk of Ovarian Cancer Cite
  Gonzalez NL, O’Brien KM, D’Aloisio AA, Sandler DP, Weinberg CR. Douching, Talc Use, and Risk of Ovarian Cancer. Epidemiology. Ovid Technologies (Wolters Kluwer Health); 2016; 27:797-802 10.1097/ede.0000000000000528
• Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study Cite
  Moslehi R, Freedman E, Zeinomar N, Veneroso C, Levine PH. Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2369-z
• Abstract C49: Relation of family history of cancer to risk of ER+, ER-, and triple-negative breast cancer in African American women Cite
  Bethea TN, Rosenberg L, Castro-Webb N, Lunetta KL, Sucheston LE, Ruiz-Narvaez EA, et al. Abstract C49: Relation of family history of cancer to risk of ER+, ER-, and triple-negative breast cancer in African American women. Organ Site Research. American Association for Cancer Research; 2016; 10.1158/1538-7755.disp15-c49
• Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients Cite
  Rachoń D. Endocrine disrupting chemicals (EDCs) and female cancer: Informing the patients. Reviews in Endocrine and Metabolic Disorders. Springer Science and Business Media LLC; 2015; 16:359-364 10.1007/s11154-016-9332-9
• Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study Cite
  Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:365-373 10.1007/s10549-016-3685-3
• Dietary intake variability in the cycle of cytotoxic chemotherapy Cite
  Mardas M, Mądry R, Stelmach-Mardas M. Dietary intake variability in the cycle of cytotoxic chemotherapy. Supportive Care in Cancer. Springer Science and Business Media LLC; 2016; 24:2619-2625 10.1007/s00520-015-3072-3
• Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation Cite
  Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility. Elsevier BV; 2016; 105:781-785 10.1016/j.fertnstert.2015.11.034
• Digitoxin enhances the growth inhibitory effects of thapsigargin and simvastatin on ER negative human breast cancer cells Cite
  Einbond LS, Wu H, Sandu C, Ford M, Mighty J, Antonetti V, et al. Digitoxin enhances the growth inhibitory effects of thapsigargin and simvastatin on ER negative human breast cancer cells. Fitoterapia. Elsevier BV; 2016; 109:146-154 10.1016/j.fitote.2015.12.005
• Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta‐analysis of observational studies Cite
  Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta‐analysis of observational studies. Cancer Medicine. Wiley; 2015; 4:1933-1947 10.1002/cam4.539
• Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy Cite
  Jordan SJ, Wilson L, Whiteman D, Webb P. Abstract 866: The proportion of breast and gynecological cancers in Australian women that can be attributed to the use of oral contraceptives and hormone replacement therapy. Epidemiology. American Association for Cancer Research; 2015; 10.1158/1538-7445.am2015-866
• Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland Cite
  Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer Risk in Women Using the Levonorgestrel-Releasing Intrauterine System in Finland. Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health); 2014; 124:292-299 10.1097/aog.0000000000000356
• BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk Cite
  Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon Y. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0127363 10.1371/journal.pone.0127363
• Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development Cite
  Delman DM, Fabian CJ, Kimler BF, Yeh H, Petroff BK. Effects of Flaxseed Lignan Secoisolariciresinol Diglucosideon Preneoplastic Biomarkers of Cancer Progression in a Model of Simultaneous Breast and Ovarian Cancer Development. Nutrition and Cancer. Informa UK Limited; 2015; 67:857-864 10.1080/01635581.2015.1042549
• Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative Cite
  Adams SV, Quraishi SM, Shafer MM, Passarelli MN, Freney EP, Chlebowski RT, et al. Dietary Cadmium Exposure and Risk of Breast, Endometrial, and Ovarian Cancer in the Women’s Health Initiative. Environmental Health Perspectives. Environmental Health Perspectives; 2014; 122:594-600 10.1289/ehp.1307054
• Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study Cite
  Charlton BM, Rich-Edwards JW, Colditz GA, Missmer SA, Rosner BA, Hankinson SE, et al. Oral contraceptive use and mortality after 36 years of follow-up in the Nurses' Health Study: prospective cohort study. BMJ. BMJ; 2014; 349:g6356-g6356 10.1136/bmj.g6356
• Low Concentration of Quercetin Antagonizes the Cytotoxic Effects of Anti-Neoplastic Drugs in Ovarian Cancer Cite
  Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, et al. Low Concentration of Quercetin Antagonizes the Cytotoxic Effects of Anti-Neoplastic Drugs in Ovarian Cancer. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e100314 10.1371/journal.pone.0100314
• ABO Blood Groups and Risk of Cancer: a Systematic Review and Meta-analysis Cite
  Zhang B, He N, Huang Y, Song F, Chen K. ABO Blood Groups and Risk of Cancer: a Systematic Review and Meta-analysis. Asian Pacific Journal of Cancer Prevention. Asian Pacific Organization for Cancer Prevention; 2014; 15:4643-4650 10.7314/apjcp.2014.15.11.4643
• Dietary Cadmium Intake and Risk of Breast, Endometrial and Ovarian Cancer in Danish Postmenopausal Women: A Prospective Cohort Study Cite
  Eriksen KT, Halkjær J, Sørensen M, Meliker JR, McElroy JA, Tjønneland A, et al. Dietary Cadmium Intake and Risk of Breast, Endometrial and Ovarian Cancer in Danish Postmenopausal Women: A Prospective Cohort Study. PLoS ONE. Public Library of Science (PLoS); 2014; 9:e100815 10.1371/journal.pone.0100815
• Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis Cite
  Friebel TM, Domchek SM, Rebbeck TR. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju091
• Pomegranate Fruit as a Rich Source of Biologically Active Compounds Cite
  Sreekumar S, Sithul H, Muraleedharan P, Azeez JM, Sreeharshan S. Pomegranate Fruit as a Rich Source of Biologically Active Compounds. BioMed Research International. Hindawi Limited; 2014; 2014:1-12 10.1155/2014/686921
• Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells Cite
  Zheng A, Chen Y, Zhao L, Feng J. Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells. Oncology Letters. Spandidos Publications; 2017; 13:4974-4978 10.3892/ol.2017.6031
• Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review Cite
  Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:1931-1943 10.1158/1055-9965.epi-13-0298
• Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells Cite
  Kang N, Hwang K, Lee H, Choi D, Choi K. Resveratrol regulates the cell viability promoted by 17β-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor α and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food and Chemical Toxicology. Elsevier BV; 2013; 59:373-379 10.1016/j.fct.2013.06.029
• Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE Cite
  Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:812-822 10.1093/jnci/djt095
• Proven non-carriers in BRCA families have an earlier age of onset of breast cancer Cite
  Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, et al. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. European Journal of Cancer. Elsevier BV; 2013; 49:2101-2106 10.1016/j.ejca.2013.02.018
• Dietary folates and cancer risk in a network of case–control studies Cite
  Tavani A, Malerba S, Pelucchi C, Dal Maso L, Zucchetto A, Serraino D, et al. Dietary folates and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2737-2742 10.1093/annonc/mds212
• 25(OH)D3 in patients with ovarian cancer and its correlation with survival Cite
  Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, Gotowska M, Walentowicz P, Krintus M, et al. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clinical Biochemistry. Elsevier BV; 2012; 45:1568-1572 10.1016/j.clinbiochem.2012.07.110
• Fertility Drugs and Young-Onset Breast Cancer: Results From the Two Sister Study Cite
  Fei C, DeRoo LA, Sandler DP, Weinberg CR. Fertility Drugs and Young-Onset Breast Cancer: Results From the Two Sister Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:1021-1027 10.1093/jnci/djs255
• Second malignancies after breast cancer: the impact of different treatment modalities Cite
  Kirova YM, De Rycke Y, Gambotti L, Pierga J, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. British Journal of Cancer. Springer Science and Business Media LLC; 2008; 98:870-874 10.1038/sj.bjc.6604241
• Increased Risk for Second Primary Malignancies in Women with Breast Cancer Diagnosed at Young Age: A Population-Based Study in Taiwan Cite
  Lee K, Chen S, Chan CH, Lu C, Chen C, Lin J, et al. Increased Risk for Second Primary Malignancies in Women with Breast Cancer Diagnosed at Young Age: A Population-Based Study in Taiwan. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2008; 17:2647-2655 10.1158/1055-9965.epi-08-0109
• Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age Cite
  Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 129:963-969 10.1007/s10549-011-1560-9
• Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden Cite
  Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. Cancer Causes & Control. Springer Science and Business Media LLC; 2012; 23:769-777 10.1007/s10552-012-9946-5
• Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study Cite
  Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study. PLoS Medicine. Public Library of Science (PLoS); 2012; 9:e1001182 10.1371/journal.pmed.1001182
• Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway Cite
  Arafa EA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, et al. Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Downregulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway. Cancer Research. American Association for Cancer Research (AACR); 2009; 69:8910-8917 10.1158/0008-5472.can-09-1543
• Cruciferous vegetables and cancer risk in a network of case–control studies Cite
  Bosetti C, Filomeno M, Riso P, Polesel J, Levi F, Talamini R, et al. Cruciferous vegetables and cancer risk in a network of case–control studies. Annals of Oncology. Elsevier BV; 2012; 23:2198-2203 10.1093/annonc/mdr604
• Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis Cite
  Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2011; 11:1197-1207 10.1586/era.11.38
• Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer Cite
  Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA. Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer. The Journal of Alternative and Complementary Medicine. Mary Ann Liebert Inc; 2013; 19:714-720 10.1089/acm.2012.0295
• P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis. Cite
  Shapira I, Budman D, Akerman M, Weiselberg L, Vinciguerra V, D'Olimpio J, et al. P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis.. Poster Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-p2-13-02
• Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry Cite
  Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:4505-4509 10.1200/jco.2010.34.4440
• Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers Cite
  Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:981-985 10.1007/s10549-011-1807-5
• Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells Cite
  Kim J, Jeong S, Kim B, Yun S, Choi DY, Kim S. Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells. Journal of Pineal Research. Wiley; 2011; 52:244-252 10.1111/j.1600-079x.2011.00935.x
• Earlier age of onset ofBRCAmutation-related cancers in subsequent generations Cite
  Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, et al. Earlier age of onset ofBRCAmutation-related cancers in subsequent generations. Cancer. Wiley; 2011; 118:321-325 10.1002/cncr.26284
• Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation Cite
  Sreeja S, Santhosh Kumar TR, Lakshmi BS, Sreeja S. Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation. The Journal of Nutritional Biochemistry. Elsevier BV; 2012; 23:725-732 10.1016/j.jnutbio.2011.03.015
• Dietary transfatty acids and cancer risk Cite
  Hu J, Vecchia CL, de Groh M, Negri E, Morrison H, Mery L. Dietary transfatty acids and cancer risk. European Journal of Cancer Prevention. Ovid Technologies (Wolters Kluwer Health); 2011; 20:530-538 10.1097/cej.0b013e328348fbfb
• Flavonoids, Proanthocyanidins, and Cancer Risk: A Network of Case-Control Studies From Italy Cite
  Rossi M, Bosetti C, Negri E, Lagiou P, Vecchia CL. Flavonoids, Proanthocyanidins, and Cancer Risk: A Network of Case-Control Studies From Italy. Nutrition and Cancer. Informa UK Limited; 2010; 62:871-877 10.1080/01635581.2010.509534
• Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations Cite
  Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, et al. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 103:1103-1108 10.1038/sj.bjc.6605876
• Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women Cite
  Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE. Analgesic Use and Sex Steroid Hormone Concentrations in Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:1033-1041 10.1158/1055-9965.epi-09-0975
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Cite
  van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:643-651 10.1007/s10549-010-0805-3
• Antibiotic use predicts an increased risk of cancer Cite
  Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heliövaara M, Huovinen P, et al. Antibiotic use predicts an increased risk of cancer. International Journal of Cancer. Wiley; 2008; 123:2152-2155 10.1002/ijc.23622
• Cancer incidence in British vegetarians Cite
  Key TJ, Appleby PN, Spencer EA, Travis RC, Allen NE, Thorogood M, et al. Cancer incidence in British vegetarians. British Journal of Cancer. Springer Science and Business Media LLC; 2009; 101:192-197 10.1038/sj.bjc.6605098
• Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening Cite
  Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics. BMJ; 2006; 44:10-15 10.1136/jmg.2006.043091
• Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 Cite
  Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:409-414 10.1007/s10549-009-0611-y
• Dietary intake and breast density in high-risk women: a cross-sectional study Cite
  Tseng M, Byrne C, Evers KA, Daly MB. Dietary intake and breast density in high-risk women: a cross-sectional study. Breast Cancer Research. Springer Science and Business Media LLC; 2007; 9 10.1186/bcr1781
• Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations Cite
  Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, et al. Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2006; 15:359-363 10.1158/1055-9965.epi-05-0687
• A two-step screening method, using estrogen receptor-mediated transactivation, to measure estrogenicity in edible plants Cite
  Arao Y, Kanamori N, Kikkawa E, Otsuka H, Arimoto Y, Ikeda K, et al. A two-step screening method, using estrogen receptor-mediated transactivation, to measure estrogenicity in edible plants. Food Chemistry. Elsevier BV; 2007; 104:1288-1294 10.1016/j.foodchem.2007.01.076
• Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort Cite
  Larsson SC, Bergkvist L, Wolk A. Milk and lactose intakes and ovarian cancer risk in the Swedish Mammography Cohort. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2004; 80:1353-1357 10.1093/ajcn/80.5.1353
• Onion and garlic use and human cancer Cite
  Galeone C, Pelucchi C, Levi F, Negri E, Franceschi S, Talamini R, et al. Onion and garlic use and human cancer. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2006; 84:1027-1032 10.1093/ajcn/84.5.1027
• Diet and Risk of Ovarian Cancer in the California Teachers Study Cohort Cite
  Chang ET, Lee VS, Canchola AJ, Clarke CA, Purdie DM, Reynolds P, et al. Diet and Risk of Ovarian Cancer in the California Teachers Study Cohort. American Journal of Epidemiology. Oxford University Press (OUP); 2007; 165:802-813 10.1093/aje/kwk065